Bispecific antibody fragments with CD20 × CD28 specificity allow effective autologous and allogeneic T-cell activation against malignant cells in peripheral blood and bone marrow cultures from patients with B-cell lineage leukemia and lymphoma

Effect of tetravalent bispecific CD19×CD

Effect of tetravalent bispecific CD19×CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells

✍ Uwe Reusch; Fabrice Le Gall; Manfred Hensel; Gerhard Moldenhauer; Anthony D. Ho; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 284 KB

## Abstract To develop an effective antitumor immunotherapy for B‐lineage non‐Hodgkin's lymphoma, we constructed a tetravalent tandem diabody (tanDb) specific for both human CD19 (B‐cell marker) and CD3 (T‐cell antigen). Here, we report the effective killing of malignant primary B cells from patien